| 摘要: |
| 原发性肝癌是最常见的恶性肿瘤之一，肝癌早期诊断困难，总体手术切除率低，而传统的非手术治疗效果欠佳。肝癌的转化治疗是通过局部/系统治疗将不可切除肝癌转为可切除肝癌，并从手术切除获益。近年来，以索拉非尼、仑伐替尼、阿帕替尼、贝伐单抗为代表的TKI/VEGF靶向治疗和PD-1/PD-L1等为代表的免疫检查点抑制剂治疗在晚期肝癌的治疗中取得重大突破，以肝动脉灌注化疗为代表的局部治疗的进步，使部分中晚期肝癌患者重新获得手术机会并因此获益。这些成果也使得肝癌的转化治疗快速发展。因此，规范的转化治疗方案是目前的研究热点，也是亟需解决和探索的问题，本文聚焦于此并对相关进展和现状进行综述。 |
| 关键词: 肝细胞癌 转化治疗 肝切除术 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| The current status and prospect of conversion therapy for hepatocellular carcinoma |
|
qinjianlun1,2,3
|
|
1.Hechi Third People'2.'3.s Hospital
|
| Abstract: |
| Primary liver cancer is one of the most common malignancies. The early diagnosis of hepatocellular carcinoma (HCC) is difficult. Conversion therapy of HCC is to transform unresectable hepatocellular carcinoma into resectable HCC and then excise it surgically. In recent years, TKI/VEGF targeted therapy represented by sorafenib, lenvatinib, apatinib, bevacizumab and immune checkpoint inhibitors therapy represented by PD-1 / PD-L1 have made a major breakthrough in the treatment of advanced HCC. Some patients with advanced HCC have regained the opportunity of operation and benefited from the progress of local treatment represented by hepatic artery infusion chemotherapy (HAIC). These results have led to the rapid development of conversion therapy for HCC. Therefore, standardized conversion therapy is not only a research hotspot, but also an urgent problem to be solved and explored. This review focuses on this and summarizes the relevant progress and current situation. |
| Key words: hepatocellular carcinoma conversion therapy hepatectomy |
